Phaseline

Companies › Hangzhou Yirui Pharmaceutical Technology

Hangzhou Yirui Pharmaceutical Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PA032
Kv1.3 potassium channel blocker
Ion channelsPhase 1Health Adult SubjectsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07673458PA032Phase 1Health Adult SubjectsOtherNov 2026

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.